CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
0.3780
3.4%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0065
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Ocugen Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.3913
Open* 0.3759
1-Year Change* -74.6%
Day's Range* 0.3715 - 0.3849
52 wk Range 0.35-1.62
Average Volume (10 days) 1.21M
Average Volume (3 months) 36.09M
Market Cap 99.27M
P/E Ratio -100.00K
Shares Outstanding 256.50M
Revenue N/A
EPS -0.32
Dividend (Yield %) N/A
Beta 3.97
Next Earnings Date Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 28, 2023 0.3780 -0.0117 -3.00% 0.3897 0.3897 0.3708
Nov 27, 2023 0.3913 -0.0006 -0.15% 0.3919 0.4044 0.3835
Nov 24, 2023 0.3949 0.0140 3.68% 0.3809 0.3969 0.3799
Nov 22, 2023 0.3799 -0.0011 -0.29% 0.3810 0.3849 0.3719
Nov 21, 2023 0.3829 -0.0098 -2.50% 0.3927 0.3995 0.3806
Nov 20, 2023 0.4046 0.0247 6.50% 0.3799 0.4085 0.3779
Nov 17, 2023 0.3860 0.0028 0.73% 0.3832 0.3883 0.3659
Nov 16, 2023 0.3608 -0.0141 -3.76% 0.3749 0.3769 0.3608
Nov 15, 2023 0.3775 0.0076 2.05% 0.3699 0.3878 0.3699
Nov 14, 2023 0.3699 0.0100 2.78% 0.3599 0.3729 0.3524
Nov 13, 2023 0.3573 -0.0027 -0.75% 0.3600 0.3609 0.3508
Nov 10, 2023 0.3599 0.0000 0.00% 0.3599 0.3699 0.3513
Nov 9, 2023 0.3579 -0.0220 -5.79% 0.3799 0.3831 0.3549
Nov 8, 2023 0.3829 0.0080 2.13% 0.3749 0.3846 0.3736
Nov 7, 2023 0.3754 -0.0025 -0.66% 0.3779 0.3829 0.3701
Nov 6, 2023 0.3779 -0.0138 -3.52% 0.3917 0.3988 0.3752
Nov 3, 2023 0.3899 0.0170 4.56% 0.3729 0.3947 0.3699
Nov 2, 2023 0.3708 0.0112 3.11% 0.3596 0.3778 0.3559
Nov 1, 2023 0.3580 -0.0077 -2.11% 0.3657 0.3666 0.3499
Oct 31, 2023 0.3624 0.0025 0.69% 0.3599 0.3748 0.3509

Ocugen, Inc. Events

Time (UTC) Country Event
Monday, February 26, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Ocugen Inc Earnings Release
Q4 2023 Ocugen Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0.04262 0 0
Revenue 0 0.04262 0
Total Operating Expense 84.868 57.628 21.3273 14.5038 28.568
Selling/General/Admin. Expenses, Total 35.111 22.92 7.97405 6.0771 10.204
Research & Development 49.757 35.108 13.3533 8.08552 15.634
Unusual Expense (Income) -0.4 0 0.34114 2.73
Operating Income -84.868 -57.628 -21.2847 -14.5038 -28.568
Interest Income (Expense), Net Non-Operating -0.079 -0.71989 -4.95401 20.031
Other, Net 3.517 -0.71 0.18266 -0.78487 -0.106
Net Income Before Taxes -81.351 -58.417 -21.822 -20.2426 -8.643
Net Income After Taxes -81.351 -58.365 -21.822 -20.2426 -8.643
Net Income Before Extra. Items -81.351 -58.365 -21.822 -20.2426 -8.643
Net Income -81.351 -58.365 -21.822 -20.2426 -8.643
Total Adjustments to Net Income 0 -12.5463 0.121
Income Available to Common Excl. Extra. Items -81.351 -58.365 -34.3683 -20.2426 -8.522
Income Available to Common Incl. Extra. Items -81.351 -58.365 -34.3683 -20.2426 -8.522
Diluted Net Income -81.351 -58.365 -34.3683 -20.2426 -8.522
Diluted Weighted Average Shares 214.6 195.013 112.236 13.8938 0.60676
Diluted EPS Excluding Extraordinary Items -0.37908 -0.29929 -0.30621 -1.45695 -14.045
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.37908 -0.30062 -0.30621 -1.4324 -9.54575
Total Extraordinary Items 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 23.733 17.751 24.15 23.119 19.565
Selling/General/Admin. Expenses, Total 9.564 8.193 6.937 7.497 10.558
Research & Development 14.169 9.558 17.213 15.622 9.007
Operating Income -23.733 -17.751 -24.15 -23.119 -19.565
Interest Income (Expense), Net Non-Operating
Net Income Before Taxes -22.925 -16.498 -21.939 -21.922 -19.471
Net Income After Taxes -22.925 -16.498 -21.939 -21.922 -19.471
Net Income Before Extra. Items -22.925 -16.498 -21.939 -21.922 -19.471
Net Income -22.925 -16.498 -21.939 -21.922 -19.471
Income Available to Common Excl. Extra. Items -22.925 -16.499 -21.939 -21.922 -19.471
Income Available to Common Incl. Extra. Items -22.925 -16.499 -21.939 -21.922 -19.471
Diluted Net Income -22.925 -16.499 -21.939 -21.922 -19.471
Diluted Weighted Average Shares 238.311 225.524 220.133 216.591 215.863
Diluted EPS Excluding Extraordinary Items -0.0962 -0.07316 -0.09966 -0.10121 -0.0902
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.0962 -0.07316 -0.09966 -0.10121 -0.0902
Revenue
Other, Net 0.808 1.253 2.211 1.197 0.094
Total Adjustments to Net Income -0.001
Unusual Expense (Income)
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 98.492 102.646 25.8777 15.7662 16.4
Cash and Short Term Investments 90.934 94.958 24.0393 7.44405 15.542
Cash & Equivalents 77.563 94.958 24.0393 7.44405 15.542
Prepaid Expenses 7.558 2.7 1.83836 1.32217 0.686
Total Assets 108.632 105.761 27.3764 16.8074 17.428
Property/Plant/Equipment, Total - Net 9.963 2.751 1.06662 0.22246 0.141
Intangibles, Net
Other Long Term Assets, Total 0.177 0.364 0.43205 0.81876 0.887
Total Current Liabilities 18.46 7 3.61355 4.54396 2.873
Accounts Payable 8.062 2.312 0.39503 1.89561 1.59
Accrued Expenses 10.398 4.688 2.97464 2.44236 1
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0.23412 0 0
Other Current Liabilities, Total 0.00976 0.20599 0.283
Total Liabilities 24.58 9.943 5.82591 5.78904 17.886
Total Long Term Debt 2.289 1.712 1.82304 1.07212 0
Long Term Debt 2.289 1.712 1.82304 1.07212
Other Liabilities, Total 3.831 1.231 0.38932 0.17295 15.013
Total Equity 84.052 95.818 21.5504 11.0184 -0.458
Common Stock 2.217 1.995 1.84133 0.52747 0.513
Additional Paid-In Capital 294.874 225.537 93.0587 62.0186 215.859
Retained Earnings (Accumulated Deficit) -213.018 -131.667 -73.3018 -51.4798 -216.83
Total Liabilities & Shareholders’ Equity 108.632 105.761 27.3764 16.8074 17.428
Total Common Shares Outstanding 221.6 199.381 184.012 52.6252 1.03376
Short Term Investments 13.371 0
Redeemable Preferred Stock 0.001 0.001 0 0
Other Equity, Total 0.026 0
Other Current Assets, Total 4.988 0 7 0.172
Property/Plant/Equipment, Total - Gross 10.584 3.125 1.29231 10.427
Accumulated Depreciation, Total -0.621 -0.374 -0.2257 -10.286
Treasury Stock - Common -0.048 -0.048 -0.04786 -0.04786
Total Preferred Shares Outstanding 0.05475
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 56.558 73.452 84.401 98.492 107.497
Cash and Short Term Investments 53.477 70.578 76.721 90.934 101.602
Cash & Equivalents 53.477 70.578 68.259 77.563 101.602
Prepaid Expenses 3.081 2.874 7.68 7.558 5.895
Other Current Assets, Total
Total Assets 74.687 88.976 96.299 108.632 116.239
Property/Plant/Equipment, Total - Net 14.469 11.72 7.952 9.963 8.557
Property/Plant/Equipment, Total - Gross 15.528 12.613 8.739 10.584 9.135
Accumulated Depreciation, Total -1.059 -0.893 -0.787 -0.621 -0.578
Other Long Term Assets, Total 3.66 3.804 3.946 0.177 0.185
Total Current Liabilities 11.136 13.46 15.683 18.46 14.907
Accounts Payable 2.921 3.881 8.092 8.062 6.46
Accrued Expenses 6.939 8.313 6.335 10.398 8.447
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1.276 1.266 1.256
Total Liabilities 16.292 18.695 20.499 24.58 20.936
Total Long Term Debt 1.495 1.472 1.058 2.289 2.265
Long Term Debt 1.495 1.472 1.058 2.289 2.265
Other Liabilities, Total 3.661 3.763 3.758 3.831 3.764
Total Equity 58.395 70.281 75.8 84.052 95.303
Common Stock 2.566 2.566 2.265 2.217 2.168
Additional Paid-In Capital 322.452 320.181 303.073 294.874 284.231
Retained Earnings (Accumulated Deficit) -266.603 -252.441 -229.516 -213.018 -191.079
Treasury Stock - Common -0.048 -0.048 -0.048 -0.048 -0.048
Other Equity, Total 0.027 0.022 0.025 0.026 0.03
Total Liabilities & Shareholders’ Equity 74.687 88.976 96.299 108.632 116.239
Total Common Shares Outstanding 256.5 256.487 226.427 221.6 216.688
Redeemable Preferred Stock 0.001 0.001 0.001 0.001 0.001
Short Term Investments 0 0 8.462 13.371
Total Preferred Shares Outstanding 0.05475 0.05475 0.05475
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -81.351 -58.365 -21.822 -20.2426 -8.643
Cash From Operating Activities -60.079 -47.941 -14.7087 -16.8933 -15.777
Cash From Operating Activities 0.48 0.229 0.10211 0.06061 0.45
Non-Cash Items 11.597 7.757 8.2213 6.40129 -14.779
Cash Taxes Paid 0 0.052 0.105
Cash Interest Paid 0.001
Changes in Working Capital 9.195 2.438 -1.21018 -3.11255 7.195
Cash From Investing Activities -16.967 -1.816 -0.30683 -2.35672 -1.113
Capital Expenditures -4.457 -1.066 -0.30683 -0.02945 -2.013
Cash From Financing Activities 59.475 120.676 31.611 25.0665 25.351
Financing Cash Flow Items -0.592 -8.525 -1.48355 -0.17293 -0.178
Issuance (Retirement) of Stock, Net 59.567 129.211 37.822 23.7294 25.529
Net Change in Cash -17.546 70.919 16.5955 5.81646 8.461
Other Investing Cash Flow Items, Total -12.51 -0.75 0 -2.32727 0.9
Issuance (Retirement) of Debt, Net 0.5 -0.01 -4.72744 1.51
Foreign Exchange Effects 0.025 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -16.498 -81.351 -59.412 -37.49 -18.019
Cash From Operating Activities -18.24 -60.079 -43.165 -28.863 -15.066
Cash From Operating Activities 0.174 0.48 0.307 0.166 0.076
Non-Cash Items 3.053 11.597 7.721 5.75 3.497
Changes in Working Capital -4.969 9.195 8.219 2.711 -0.62
Cash From Investing Activities 3.441 -16.967 -1.672 -1.589 -0.223
Capital Expenditures -1.612 -4.457 -2.433 -1.589 -0.223
Cash From Financing Activities 5.496 59.475 51.3 50.338 50.102
Financing Cash Flow Items -0.235 -0.592 -0.398 -0.248 -0.075
Issuance (Retirement) of Stock, Net 5.731 59.567 51.198 50.586 50.177
Issuance (Retirement) of Debt, Net 0.5 0.5 0 0
Net Change in Cash -9.304 -17.546 6.493 19.896 34.813
Other Investing Cash Flow Items, Total 5.053 -12.51 0.761 0
Cash Taxes Paid 0 0
Foreign Exchange Effects -0.001 0.025 0.03 0.01
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.6031 11806345 -1208505 2023-06-30 LOW
Luminus Management, L.L.C. Hedge Fund 1.5904 4079238 4079238 2023-06-30 MED
GMT Capital Corp. Hedge Fund 1.5292 3922198 3922198 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.5146 3884853 -10098331 2023-06-30 LOW
Millennium Management LLC Hedge Fund 1.1761 3016537 1748855 2023-06-30 HIGH
JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 1.1354 2912274 -62660 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.1162 2862968 -1798365 2023-06-30 LOW
Alyeska Investment Group, L.P. Hedge Fund 0.9747 2500000 2500000 2023-06-30 HIGH
Renaissance Technologies LLC Hedge Fund 0.9635 2471156 189608 2023-06-30 HIGH
KVM Holdings, L.L.C. Corporation 0.4465 1145299 0 2023-04-13
Charles Schwab Investment Management, Inc. Investment Advisor 0.4421 1134020 -384808 2023-06-30 LOW
D. E. Shaw & Co., L.P. Hedge Fund 0.4259 1092269 1092269 2023-06-30 MED
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 0.4215 1081149 1081149 2023-06-30 MED
Susquehanna International Group, LLP Investment Advisor 0.4082 1047001 -1373928 2023-06-30 MED
Zhang (Junge) Individual Investor 0.3762 964904 0 2023-04-13
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.3437 881626 -5189880 2023-06-30 LOW
Kompella (Uday B.) Individual Investor 0.2749 705090 0 2023-04-13
Citadel Advisors LLC Hedge Fund 0.2235 573323 279457 2023-06-30 LOW
Musunuri (Shankar Ph.D) Individual Investor 0.1886 483636 -1359897 2023-04-13 HIGH
Jane Street Capital, L.L.C. Research Firm 0.1819 466625 33988 2023-06-30 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Ocugen, Inc. Company profile

Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine. 

Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.

Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. 

For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.

The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).

The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD). 

Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.

Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.

Ocugen is headquartered in Malvern, Pennsylvania.

Industry: Biotechnology & Medical Research (NEC)

11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US

Income Statement

  • Annual
  • Quarterly

News

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

Gold Rises as Traders price-in Fed Rate Cuts

Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

13:17, 20 November 2023

People also watch

Gold

2,038.93 Price
-0.110% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.62 Price
-0.330% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

38,189.85 Price
+0.460% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

16,075.70 Price
+0.430% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading